Ezatiostat

DB05460InvestigationalSmall molecule

Ezatiostat is investigated in clinical trials for treating myelodysplastic syndrome. This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid... These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom...

Mechanism: Pharmacologically active on Glutathione S-transferase P
Curator reviewed
Primary indication: Investigated for use/treatment in myelodysplastic syndrome.Curator reviewed
Formula / weight: C₂₇H₃₅N₃O₆S · 529.648 g/mol (avg)
Code names: Ter-199 · Terrapin 199 · TLK-199

Resolves to

Compound

UNII057D10I8S8CAS168682-53-9ChEMBLCHEMBL2110585PubChem5310939

Structure

InChIKeyGWEJFLVSOGNLSS-WPFOTENUSA-NSMILESCCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCC1=CC=CC=C1)C(=O)N[C@@H](C(=O)OCC)C1=CC=CC=C1

Targets

P09211GSTP1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ezatiostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account